• ArmaGen Receives Orphan Drug Designation for AGT-184 americanpharmaceuticalreview
    August 03, 2018
    ArmaGen announced the U.S. Food and Drug Administration's (FDA) Office of Orphan Products Development granted Orphan Drug Designation to GT-184 for the treatment of mucopolysaccharidosis type IIIA (also known as Sanfilippo Syndrome A or MPS IIIA).
PharmaSources Customer Service